Patents
Literature
38 results about "Endoglycosidase" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
An Endoglycosidase is an enzyme that releases oligosaccharides from glycoproteins or glycolipids. It may also cleave polysaccharide chains between residues that are not the terminal residue, although releasing oligosaccharides from conjugated protein and lipid molecules is more common.
Core fucosylated glycopeptides and glycoproteins: chemoenzymatic synthesis and uses thereof
ActiveUS20120226024A1Prolonged half-life-timeLess immunogenicityImmunoglobulins against animals/humansEnzymesFucosylationEndorhamnosidase
A chemoenzymatic method for the preparation of a core-fucoslyated glycoprotein or glycopeptide, including (a) providing an acceptor selected from the group consisting of a fucosylated GlcNAc-protein and fucosylated GlcNAc-peptide; and (b) reacting the acceptor with a donor substrate including an activated oligosaccharide moiety, in the presence of an endoglycosidase (ENGase) selected from Endo;F1, Endo-F2, Endo-F3, Endo-D and related glycosynthase mutants to transfer the oligosaccharide moiety to the acceptor and yield the structure defined core-fucosylated glycoprotein or glycopeptide. The donor substrate includes, in a specific implementation, a synthetic oligosaccharide oxazoline. A related method of fucosylated glycoprotein or fucosylated glycopeptide remodeling with a predetermined natural N-glycan or a tailor-made oligosaccharide moiety, and a method of remodeling an antibody to include a predetermined sugar chain to replace a heterogeneous sugar chain, are also described.
Owner:UNIV OF MARYLAND BALTIMORE
Glycoprotein synthesis and remodeling by enzymatic transglycosylation
ActiveUS7807405B2Prolonged half-life-timeLess immunogenicVirus peptidesPeptide preparation methodsHalf-lifeGlycopeptide
A chemoenzymatic method for the preparation of a homogeneous glycoprotein or glycopeptide, including (a) providing an acceptor selected from the group consisting of GlcNAc-protein and GlcNAc-peptide; and (b) reacting the acceptor with a donor substrate including an activated oligosaccharide moiety, in the presence of a catalyst comprising endoglycosidase (ENGase), to transfer the oligosaccharide moiety to the acceptor and yield the homogeneous glycoprotein or glycopeptide. The donor substrate includes, in a specific implementation, a synthetic oligosaccharide oxazoline. A related method of glycoprotein or glycopeptide remodeling with a predetermined natural N-glycan or a tailor-made oligosaccharide moiety, and a method of remodeling an antibody including a heterogeneous sugar chain, are also described. The disclosed methodology enables glycoprotein drugs to be modified for prolonged half-life in vivo, reduced immunogenicity, and enhanced in vivo activity, and for targeting and drug delivery.
Owner:UNIV OF MARYLAND
Method for determining endoglycosidase enzyme activity
ActiveUS20060127945A1Improve throughputMicrobiological testing/measurementLibrary screeningEndorhamnosidaseHeparanase
The invention relates to a method for determining endoglycosidase enzyme activity, and in particular of the heparanase type, in a sample, and also to a method for detecting a compound capable of modulating the activity of an endoglycosidase, and in particular of an endoglycosidase having activity of the heparanase type, by measuring a signal resulting from a close proximity transfer between two compounds attached to a substrate for the enzyme.
Owner:CIS BIO INT
Glycoprotein synthesis and remodeling by enzymatic transglycosylation
ActiveUS20080138855A1Prolonged half-life-timeLess immunogenicImmunoglobulins against animals/humansDepsipeptidesHalf-lifeGlycopeptide
A chemoenzymatic method for the preparation of a homogeneous glycoprotein or glycopeptide, including (a) providing an acceptor selected from the group consisting of GlcNAc-protein and GlcNAc-peptide; and (b) reacting the acceptor with a donor substrate including an activated oligosaccharide moiety, in the presence of a catalyst comprising endoglycosidase (ENGase), to transfer the oligosaccharide moiety to the acceptor and yield the homogeneous glycoprotein or glycopeptide. The donor substrate includes, in a specific implementation, a synthetic oligosaccharide oxazoline. A related method of glycoprotein or glycopeptide remodeling with a predetermined natural N-glycan or a tailor-made oligosaccharide moiety, and a method of remodeling an antibody including a heterogeneous sugar chain, are also described. The disclosed methodology enables glycoprotein drugs to be modified for prolonged half-life in vivo, reduced immunogenicity, and enhanced in vivo activity, and for targeting and drug delivery.
Owner:UNIV OF MARYLAND BALTIMORE
Method for preparing glycan-hydrolyzed antibody, and homogeneous glycosylated antibody
ActiveUS9550834B2Superior in attachment to Fc receptorEfficient productionMicrobiological testing/measurementBiological material analysisGlycosideProteinase activity
The present invention is aimed to provide a method for preparing an acceptor that is N-glycan hydrolyzed antibody or a Fc fragment thereof used for producing antibody having a homogeneous N-glycan structure; a method for determining a combination of endoglycosidases for use in said preparation; and a method for measuring N-glycans linked to an antibody. The present invention is directed to a method for producing a N-glycan hydrolyzed antibody or Fc fragment thereof, comprising reacting the antibody or the Fc fragment thereof with several endoglycosidases; and a method for determining quantitative information of an objective N-glycan with a desired structure linked to an antibody or a Fc thereof, comprising a protease treatment step and a glycopeptide measurement step, etc.
Owner:NOGUCHI INST +1
Method for analyzing protein O-glycosylation sites
The invention relates to a method for analyzing protein O-glycosylation sites. The method comprises the following steps: (1), sequentially carrying out endonuclease digestion, endoglycosidase and exoglycosidase digestion on a proteome sample or a single protein sample to prepare a peptide and non-glycopeptide protein sample or single protein sample with a GalNAc label; (2) loading the sample on a durian agglutinin chromatographic column and separating to prepare a proteomic sample; (3) separating the single protein sample or the proteomic sample through with a C18 reversed-phase chromatographic column, and then detecting by a high-definition mass spectrometer in a cation mode to obtain a high-definition mass spectrogram; (4) processing the obtained mass spectrometric data and obtaining protein glycosylation site information though the searched result. The site information can be more rapidly, more accurately and more comprehensively obtained through establishing the method for detecting the O-glycosylation sites of glycoproteins in the single protein sample and the proteomic sample.
Owner:SHANDONG UNIV
Use of the endoglycosidase endos for treating immunoglobulin g mediated diseases
The invention provides use of an EndoS polypeptide, or a polynucleotide encoding an EndoS polypeptide, in the manufacture of a medicament for the treatment or prevention of a disease or condition mediated by IgG antibodies.
Owner:ハンサバイオファルマアクチボラゲット
Endoglycosidase from Streptococcus pyogenes and methods using it
ActiveUS9493752B2Microbiological testing/measurementImmunoglobulinsStreptococcus pyogenesEndorhamnosidase
Owner:GENOVIS AB
Use of non-catalytic form of heparanase and peptides thereof for reversing the Anti-coagulant effects of heparinoids
InactiveUS20110104140A1Peptide/protein ingredientsMicrobiological testing/measurementMedicineHeparinoids
The present invention relates to inhibition of heparinoids anti-coagulation activity by a non-active form of a eukaryotic endoglycosidase or any fragment or peptide thereof comprising at least one heparin-binding domain. More particularly, the invention provides compositions and methods for the inhibition of heparinoids anti-coagulation activity and for the treatment of coagulation related pathologic clinical conditions, using a non-active form of mammalian heparanase or peptides thereof comprising at least one heparin-binding domain.
Owner:HADASIT MEDICAL RES SERVICES & DEVMENT +1
Method for catalyzing isotope labeled N-sugar chain by using endoglycosidase
The invention belongs to the technical field of analytical chemistry, and particularly relates to a method for catalyzing an isotope labeled N-sugar chain by using endoglycosidase. Glycoprotein enzymolysis reaction of the endoglycosidase is performed in 18O water, and when the N-sugar chain is digested by enzyme, an isotope 18O molecule is labeled at the reductive tail end of the N-sugar chain. Mass spectrometric detection results prove that the difference between the isotope 18O labeled sugar chain molecular weight and the unlabeled sugar chain molecular weight is 2 Daltons and the isotope 18O molecule is stably labeled at the reductive tail end of the sugar chain. The method is simple and efficient, fills the blank of the sugar chain isotope 18O labeling technology, and can be effectively used for relative quantification of the sugar chain.
Owner:FUDAN UNIV
Means and methods for detecting endoglycosidase activity
InactiveUS20050158814A1Simple and convenient chitotriosidase determinationImprove the level ofSugar derivativesHydrolasesGlycosideSynthesis methods
The invention discloses a method for detecting an activity of an endoglycosidase. The method includes providing the endoglycosidase with a substrate of the endoglycosidase and detecting cleavage of the substrate. The method further includes at least partly inhibiting the transglycosidase activity of the endoglycosidase. The transglycosidase activity may be inhibited by chemically modifying the substrate such that transglycosylation of the substrate by the endoglycosidase is at least partly inhibited while the endoglycosidase is still capable of cleaving the substrate. In one embodiment, the substrate comprises an oligosaccharide chain. Compounds and kits suitable for use in a method of the invention are also disclosed. Methods involving competitive inhibitors are also disclosed as are methods for the synthesis of glycosylated substrates involving the transglycosidase activity of an endoglycosidase.
Owner:ACADEMISCH ZIEKENHUIS BIJ DE UNIV VAN AMSTERDAM ACADEMISCH MEDISCH CENT
Preparation method of egg source protein powder with high characteristics and protein powder prepared by using preparation method
PendingCN109965076AImprove immune activityPromote digestion and absorptionProtein composition from eggsFood ingredient functionsWater bathsNeutral protease
Owner:HUAZHONG AGRI UNIV
Method for preparing glycan-hydrolyzed antibody, and homogeneous glycosylated antibody
ActiveUS20160032010A1Superior in attachment to Fc receptorEfficient productionMicrobiological testing/measurementBiological material analysisGlycosideGlycan
The present invention is aimed to provide a method for preparing an acceptor that is N-glycan hydrolyzed antibody or a Fc fragment thereof used for producing antibody having a homogeneous N-glycan structure; a method for determining a combination of endoglycosidases for use in said preparation; and a method for measuring N-glycans linked to an antibody. The present invention is directed to a method for producing a N-glycan hydrolyzed antibody or Fc fragment thereof, comprising reacting the antibody or the Fc fragment thereof with several endoglycosidases; and a method for determining quantitative information of an objective N-glycan with a desired structure linked to an antibody or a Fc thereof, comprising a protease treatment step and a glycopeptide measurement step, etc.
Owner:NOGUCHI INST +1
Methods for producing recombinant glycoproteins with modified glycosylation
Genetically engineered host animal cells capable of producing glycoproteins having modified glycosylation patterns, e.g., defucosylation and / or monoglycosylation. Such host animal cells can be engineered to express fucosidase, endoglycosidase or both.
Owner:ONENESS BIOTECH
Endoglycosidase mutants for glycoprotein remodeling and methods of using it
ActiveUS20180298361A1Reduced hydrolyzing activityExcellent transglycosylation activityImmunoglobulins against cell receptors/antigens/surface-determinantsAntibody ingredientsWild typeEndorhamnosidase
A mutant of Endos2 includes one or more mutations in the sequence of a wild-type EndoS2 (SEQ ID NO:1), wherein the one or more mutations are in a peptide region located within residues 133-143, residues 177-182, residues 184-189, residues 221-231, and / or residues 227-237, wherein the mutant of EndoS2 has a low hydrolyzing activity and a high tranglycosylation activity, as compared to those of the wild-type EndoS2. A method for preparing an engineered glycoprotein using the mutant of EndoS2 includes coupling an activated oligosaccharide to a glycoprotein acceptor. The activated oligosaccharide is a glycan oxazoline.
Owner:CHO PHARMA INC +1
Means and methods for detecting endoglycosidase activity
InactiveUS7632654B2Inhibitory activitySimple and reliable test for determining the activitySugar derivativesHydrolasesDisaccharidaseEndorhamnosidase
The invention discloses a method for detecting an activity of an endoglycosidase. The method includes providing the endoglycosidase with a substrate of the endoglycosidase and detecting cleavage of the substrate. The method further includes at least partly inhibiting the transglycosidase activity of the endoglycosidase. The transglycosidase activity may be inhibited by chemically modifying the substrate such that transglycosylation of the substrate by the endoglycosidase is at least partly inhibited while the endoglycosidase is still capable of cleaving the substrate. In one embodiment, the substrate comprises an oligosaccharide chain. Compounds and kits suitable for use in a method of the invention are also disclosed. Methods involving competitive inhibitors are also disclosed as are methods for the synthesis of glycosylated substrates involving the transglycosidase activity of an endoglycosidase.
Owner:ACADEMISCH ZIEKENHUIS BIJ DE UNIV VAN AMSTERDAM ACADEMISCH MEDISCH CENT
Combined therapeutic use of antibodies and endoglycosidases
InactiveCN108619509AAntibacterial agentsPeptide/protein ingredientsTherapeutic antibodyAntiendomysial antibodies
The invention relates to compositions comprising therapeutic antibodies, and uses and methods for increasing the potency of therapeutic antibodies. In particular, the invention provides a compositioncomprising (i) an agent which reduces Fc receptor binding of endogenous serum antibodies, and (ii) a therapeutic antibody, preferably a therapeutic antibody which is resistant to the agent. The therapeutic antibody may be administered to the subject after a set time interval, or the blood of the subject may be treated with the agent prior to administration of the therapeutic antibody.
Owner:ハンサバイオファルマアクチボラゲット
Novel glycosphingolipid endoglycosidase, and gene engineering preparation method and application thereof
The invention relates to a method for realizing the engineering expression of glycosyl endoglycosidase EGCase I. The method can realize the effective soluble expression of the EGCase I and maintain excellent hydrolysis and transglycosylation activity; a novel EGCase I mutant enzyme developed on the basis of the method has a broad substrate spectrum, and also has the activity of glycosidase synthetase; and the obtained glycosphingolipid endoglycosidase is very suitable for being applied to the analysis and the synthesis of industrial glycosphingolipids.
Owner:SHANGHAI JIAO TONG UNIV +1
A method for analyzing protein O-glycosylation sites
The invention relates to a method for analyzing protein O-glycosylation sites. The method comprises the following steps: (1), sequentially carrying out endonuclease digestion, endoglycosidase and exoglycosidase digestion on a proteome sample or a single protein sample to prepare a peptide and non-glycopeptide protein sample or single protein sample with a GalNAc label; (2) loading the sample on a durian agglutinin chromatographic column and separating to prepare a proteomic sample; (3) separating the single protein sample or the proteomic sample through with a C18 reversed-phase chromatographic column, and then detecting by a high-definition mass spectrometer in a cation mode to obtain a high-definition mass spectrogram; (4) processing the obtained mass spectrometric data and obtaining protein glycosylation site information though the searched result. The site information can be more rapidly, more accurately and more comprehensively obtained through establishing the method for detecting the O-glycosylation sites of glycoproteins in the single protein sample and the proteomic sample.
Owner:SHANDONG UNIV
Rapid and efficient de-glycosylation of glycoproteins
ActiveUS20200291377A1Stable denatured glycoproteinHydrolasesMaterial analysis by electric/magnetic meansCapillary electrophoresisActive agent
The present invention discloses rapid and cost-effective method of de-glycosyation of a glycoprotein, wherein, glycoprotein is combined with anionic surfactant and reducing agent and non-ionic surfactant in order to obtain stable denatured glycoprotein. An endoglycosidase is further added to denatured glycoprotein to cleave N-linked glycans in order to obtain de-glycosylated protein. A rapid tool for assessing the protein conformation by partial de-glycosylation is also presented wherein the partial de-glycosylated protein is analysed using capillary electrophoresis (CE-SDS).
Owner:BIOCON LTD
Use of non-catalytic form of heparanase and peptides thereof for reversing the anti-coagulant effects of heparinoids
The present invention relates to inhibition of heparinoids anti-coagulation activity by a non-active form of a eukaryotic endoglycosidase or any fragment or peptide thereof comprising at least one heparin-binding domain. More particularly, the invention provides compositions and methods for the inhibition of heparinoids anti-coagulation activity and for the treatment of coagulation related pathologic clinical conditions, using a non-active form of mammalian heparanase or peptides thereof comprising at least one heparin-binding domain.
Owner:HADASIT MEDICAL RES SERVICES & DEVMENT +1
Method for determining endoglycosidase enzyme activity
The invention relates to a method for determining endoglycosidase enzyme activity, and in particular of the heparanase type, in a sample, and also to a method for detecting a compound capable of modulating the activity of an endoglycosidase, and in particular of an endoglycosidase having activity of the heparanase type, by measuring a signal resulting from a close proximity transfer between two compounds attached to a substrate for the enzyme.
Owner:CIS BIO INT
Fusion protein for remodeling antibody glycoform
PendingUS20210040463A1Facilitates enzyme synergismGood effectAntibody mimetics/scaffoldsGlycosylasesGlycanEndorhamnosidase
The present disclosure provides a fusion protein comprising a fucosidase or a truncated fragment or a mutant thereof fuses with either N-terminal end or C-terminal end of the endoglycosidase or a truncated fragment of mutant thereof. The present disclosure also provides a nucleic acid molecule expressing the fusion protein and a method for remodeling a glycan of an antibody Fc region.
Owner:CHO PHARMA INC
Method for producing recombinant glycoprotein with modified glycosylation
Genetically engineered host animal cells are capable of producing glycoproteins with modified glycosylation patterns, such as defucosylation and / or monoglycosylation. Such host animal cells can be engineered to express fucosidases, endoglycosidases, or both.
Owner:ONENESS BIOTECH
Endoglycosidase mutants for glycoprotein remodeling and methods of using it
A mutant of EndoS2 includes one or more mutations in the sequence of a wild-type EndoS2 (SEQ ID NO: 1), wherein the one or more mutations are in a peptide region located within residues 133-143, residues 177-182, residues 184-189, residues 221-231, and / or residues 227-237, wherein the mutant of EndoS2 has a low hydrolyzing activity and a high tranglycosylation activity, as compared to those of thewild-type EndoS2. A method for preparing an engineered glycoprotein using the mutant of EndoS2 includes coupling an activated oligosaccharide to a glycoprotein acceptor. The activated oligosaccharideis a glycan oxazoline.
Owner:CHO PHARMA INC +1
Fusion protein for remodeling antibody glycoform
The present disclosure provides a fusion protein comprising a fucosidase or a truncated fragment or a mutant thereof fuses with either N-terminal end or C-terminal end of the endoglycosidase or a truncated fragment of mutant thereof. The present disclosure also provides a nucleic acid molecule expressing the fusion protein and a method for remodeling a glycan of an antibody Fc region.
Owner:CHO PHARMA INC
Method for determining endoglycosidase (heparanase) enzyme activity
InactiveUS8003339B2Modulate activity of enzymeQuick filterCompound screeningApoptosis detectionEndorhamnosidaseHepsin
The present invention provides a method for determining endoglycosidase activity, and in particular of the heparanase type, in a sample, and also a method for detecting compounds that modulate the activity of endoglycosidases and in particular endoglycosidases of the heparanase type.
Owner:HAUBECK HANS DIETER
Methods of treating tumors
PendingUS20220233689A1Peptide/protein ingredientsPharmaceutical delivery mechanismAntiendomysial antibodiesEndorhamnosidase
The disclosure provides pharmaceutical compositions comprising an anti-PD-1 antibody or an anti-PD-L1 antibody. In some aspects, the pharmaceutical compositions are formulated for subcutaneous delivery. In some aspects, the pharmaceutical compositions further comprise an endoglycosidase hydrolase enzyme. Other aspects of the present disclosure are directed to methods of subcutaneously delivering a pharmaceutical composition comprising an anti-PD-1 antibody or an anti-PD-L1 antibody.
Owner:HALOZYME
A novel glycosphingolipid endoglycosidase and its genetic engineering preparation method and application
The present invention relates to a method capable of realizing the engineered expression of glycosphingolipid endoglycosidase EGCase I, which can effectively express EGCase I in a soluble manner, and maintain excellent hydrolysis and transglycoside activity; and on this basis, A new type of EGCase I mutant enzyme was further developed, which not only has a wider substrate spectrum, but also has glycoside synthase activity; the obtained glycosphingolipid endoglycosidase is very suitable for the analysis of industrial glycosphingolipids and synthesis.
Owner:SHANGHAI JIAO TONG UNIV +1
Use of the endoglycosidase Endos for treating immunoglobulin g mediated diseases
Owner:ハンサバイオファルマアクチボラゲット
PatSnap Eureka turns technology decisions into work you can execute. Powered by our Innovation Knowledge Graph, it runs expert workflows across engineering, life sciences, materials and intellectual property. Get your review-ready output in minutes.
